Expected to grow at a CAGR of over 6% through 2033, the NEC drugs market is driven by increasing neonatal intensive care admissions and research in early-stage therapeutics. Probiotics, biologics, and targeted antibiotics remain at the forefront of innovation, supported by clinical trials and public-private healthcare initiatives. https://www.datamintelligence.com/research-report/phosphoglucomutase-deficiency-market